1. Academic Validation
  2. Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists

Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists

  • Bioorg Med Chem Lett. 2018 Feb 15;28(4):711-719. doi: 10.1016/j.bmcl.2018.01.014.
Serge Pieters 1 David McGowan 2 Florence Herschke 2 Frederik Pauwels 2 Bart Stoops 2 Stefaan Last 2 Werner Embrechts 2 Annick Scholliers 2 Wendy Mostmans 2 Kris Van Dijck 2 Bertrand Van Schoubroeck 2 Tine Thoné 2 Dorien De Pooter 2 Gregory Fanning 2 Mari Luz Rosauro 3 Mourad Daoubi Khamlichi 3 Ioannis Houpis 2 Eric Arnoult 4 Tim H M Jonckers 2 Pierre Raboisson 2
Affiliations

Affiliations

  • 1 Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium. Electronic address: spieters@its.jnj.com.
  • 2 Janssen Infectious Diseases Diagnostics BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium.
  • 3 Villapharma Research S.L., Parque Tecnológico de Fuente Álamo, Ctra. El Estrecho-Lobosillo, km. 2.5-Av. Azul, 30320 Fuente Álamo de Murcia, Murcia, Spain.
  • 4 Janssen Research & Development L.L.C., 1400 McKean Rd, Spring House, PA 19454, United States.
Abstract

The discovery of a novel series of highly potent quinazoline TLR 7/8 agonists is described. The synthesis and structure-activity relationship is presented. Structural requirements and optimization of this series toward TLR 7 selectivity afforded the potent agonist 48. Pharmacokinetic and pharmacodynamic studies highlighted 48 as an orally available endogenous interferon (IFN-α) inducer in mice.

Keywords

HBV; Quinazoline; TLR7.

Figures
Products